33 results about "Nitric oxide synthase" patented technology

The invention discloses application of polyol nitrate in frostbite resistance, and belongs to the technical field of skin protection articles. The polyol nitrate is used as an active component of the ointment, and by slowly releasing nitric oxide and activating vascular endothelial nitric oxide synthase, spasm capillaries in the early stage of frostbite are effectively relaxed, platelet aggregation and thrombosis are inhibited, so that the pathological cascade reaction of frostbite is blocked, and the prevention and treatment effects on frostbite are remarkably improved. Compared with the prior art, the polyol nitrate and the ointment are scientific and reasonable in preparation method and safe and convenient to use, and a brand-new and effective solution is provided for prevention and treatment of skin frostbite in a cold environment.

The invention provides a tissue engineering heart valve stent with a sulfonated nano-enzyme coating as well as a preparation method and application of the tissue engineering heart valve stent, and belongs to the technical field of medical materials. The invention relates to a tissue engineering heart valve stent with a sulfonated nano-enzyme coating, which comprises an acellular matrix carrier, ruthenium / iridium-tannic acid nano-enzyme loaded on the acellular matrix carrier, and a sulfonated polymer coating fixed on the acellular matrix carrier and / or the surface of nano-particles through ultraviolet polymerization, the ruthenium / iridium-tannic acid nano-enzyme is formed by tannic acid TA, Ru < 3 + > and Ir < 3 + > through coordination. According to the invention, through double bionic activities of superoxide dismutase and nitric oxide synthase of ruthenium / iridium-tannic acid nano-enzyme and through the super-hydrophilicity and electrically neutral surface of the sulfonated polymer coating, collaborative regulation and control of O2-NO cascade catalysis and interface functions in a pathological microenvironment are realized; the structural and functional in-situ regeneration of the tissue engineering heart valve stent is promoted.

The invention provides new pharmacological approaches to the treatment of benign and malignant primary brain tumors, and specifically glioblastomas (GBM) and astrocytomas in which treatment is complicated by resistance to conventional chemotherapies. To which end the invention provides compositions and methods using modulators of intracellular nitrosative / oxidative stress and modulators DNA replication and apoptosis, with examples of specific inhibitors of neuronal and inducible NO synthetases (nNOS and iNOS) that were found to be effective either when administered alone or more effective when administered in combination temozolomide (TMZ), even in tumors displaying TMZ resistance.

The invention belongs to the technical field of biological medicine, and particularly relates to coriaria sinica lactone compounds, a preparation method thereof and application of the coriaria sinica lactone compounds in anti-inflammatory activity. The coriaria sinica lactone compound can significantly inhibit a TLR4 / NF-kappa B signal channel to inhibit downstream inflammatory protein nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and further inhibit inflammatory BV2 cells from generating nitric oxide, the inhibition rate can reach 65.5%, and it is indicated that the coriaria sinica lactone compound has an application prospect in treatment of neuroinflammatory diseases.

The invention relates to application of 6 '-O-caffeoyl arbutin in preparation of a medicine for treating dementia, and belongs to the technical field of biological medicine. The 6 '-O-caffeoyl arbutin disclosed by the invention has a remarkable dementia treatment value, the action mechanism accurately fits the core pathological process of dementia, a neuroprotective effect is played by relieving oxidative stress and inhibiting inflammatory reaction, oxidative stress related indexes such as superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) can be effectively adjusted, and the dementia treatment effect is improved. The release of lactic dehydrogenase (LDH) and malondialdehyde (MDA) and the level of damage-induced nitric oxide synthase (I NOS) are reduced, so that the NMDA-induced PC12 cell damage is protected.

A pharmaceutical composition for producing a safe amount of nitric oxide (NO) in vivo and use thereof. The pharmaceutical composition comprises the following components: an NO toxicity decreasing agent, an optional NO extender, and a nitric oxide synthase inducer. Provided is the pharmaceutical composition which has high versatility and extremely effectively treats pathogenic microorganism infections. A new medicinal activity of 5-methyltetrahydrofolic acid, NMN, and dehydroascorbic acid is found, which has a variety of active effects on an immune system caused by pathogen infection, and capable of being used for treating or preventing disease caused by virus infections and other pathogen infections.

The invention discloses a sesquiterpene compound as well as a preparation method and application thereof, and relates to the technical field of medicines. The invention provides a sesquiterpene compound and discloses new activity of the sesquiterpene compound, namely the sesquiterpene compound is used for remarkably inhibiting generation of inflammatory BV2 cell NO and remarkably inhibiting oxidative stress SH-SY5Y cell damage. The sesquiterpene compound can significantly inhibit TLR4 / NF-kappa B signal channels to inhibit expression of downstream inflammatory protein nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and has an application prospect in treatment of neuroinflammatory diseases. The invention can obtain the sesquiterpene compound as well as the preparation method and the application thereof.

The application discloses a kind of micro bone-blood vessel symbiosis based on gene activation and its preparation method and application.The system includes: the amorphous calcium phosphate nanoparticles of L-arginine, bovine serum albumin and alendronate sodium co-modified loaded BMP-2 mRNA;Methacrylic acid gel hydrogel microspheres encapsulating the nanoparticle;And E7 peptide grafted on the surface of hydrogel microspheres.It is captured by E7 peptide bone marrow mesenchymal stem cells, and delivers BMP-2 mRNA to activate intracellular BMP-2 and endothelial-type nitric oxide synthase expression, while using L-arginine to drive in-situ synthesis of nitric oxide, to synergistically enhance stem cell osteogenic differentiation and promote vascular sprouting ability, realize the vascularization synchronous regeneration of bone defect.The system solves the problem of unstable exogenous nitric oxide donor and bone-vessel regeneration decoupling, and has excellent biocompatibility and bone repair efficiency.

A nutritional supplement includes one or more immune modulators that support a subject's cellular immunity, as well as ingredients that enhance the production and use of nitric oxide by the subject's body to better regulate the subject's cellular immunity. Such a nutritional supplement may include nano-fraction immune modulators, transfer factor, or plant transfer factor, as well as sufficient amounts of vitamin B9 and vitamin B12 to increase endothelial nitric oxide synthetase activity in a body of a subject. Methods for increasing endothelial nitric oxide synthetase activity in the body of a subject are also disclosed.

A process for the preparation of racemic and optically active (1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N′-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide in high enantiomerical purity is provided.

The invention relates to a composition and a preparation method of a reproduction nursing external preparation with effects of inhibiting bacteria, relieving and improving male functions. The invention discloses an external preparation for male reproduction nursing. The plant essential oil comprises natural plant extracts (clove, herba epimedii, ginseng, dendrobium officinale, tribulus terrestris, radix sophorae flavescentis, fructus cnidii, saw palmetto fruit and aloe vera), nutritional ingredients (arginine, hydrolyzed collagen zinc, nicotinic acid, tocopherol, biotin and B-group vitamin yeast polypeptide) and compound essential oil (tea tree oil, jasmine flower oil, iris oil, cananga odorata flower oil and sandalwood oil). The composition can be prepared into spray, cream, lotion and other dosage forms. The preparation improves erectile function, enhances microcirculation, relieves pressure, improves sexual desire and realizes precise adjustment of male function and protection of gonad axis through mechanisms of inhibiting bacteria, diminishing inflammation, improving testosterone concentration, enhancing nitric oxide synthase activity, promoting vasodilatation, blocking neural signals, delaying ejaculation and the like.

A method for the in vitro diagnosis of the risk of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage from a ruptured aneurysm (aSAH) which includes the following steps: collection of a blood sample from the patient; quantitative determination of 8-iso-prostaglandin F2α (F2-IsoP) concentration in plasma; comparison of the concentration thereof in plasma with the reference value; collection of at least one further blood sample; quantitative determination of the concentration of endothelial nitric oxide synthase (eNOS) and / or nicotinamide adenine dinucleotide phosphate (NADPH) in plasma; comparison of the concentration thereof in plasma with the reference value; analysis of the obtained results and establishing diagnosis. A marker substance for the in vitro diagnosis of the risk of occurrence of DCI selected from 8-iso-prostaglandin F2α (F2-IsoP), endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) and combinations thereof and the use thereof as a screening test for the in vitro diagnosis of DCI following aSAH.

A novel microparticle which comprises a miRNA that regulates the production of nitric oxide, is a nitric oxide production promoter, and is capable of regulating the expression of a protein and / or a gene associated with erectile dysfunction; a prophylactic or therapeutic agent for erectile dysfunction; a method for improving erectile dysfunction; the particles are preferably exosomes; it is preferable that the microparticles comprise, as a miRNA for regulating the production of nitric oxide, miRNA having a gene related to the expression of nitric oxide synthase as a target gene, and are an expression promoter for nitric oxide synthase.

Preparation method and application of diterpenoid, relate to the application technical field of diterpenoid.The present application separates two new compounds of diterpenoid A and diterpenoid B from a strain of Hericium fermentation extract, and discloses chemical structural formula of the two compounds, and corresponding nuclear magnetic, mass spectrum, infrared and ultraviolet data, and its function of significantly inhibiting the production of inflammatory BV2 cell NO.Diterpenoid B has 24% of the promotion rate of axon growth of PC-12 cell, and simultaneously has significant inhibition of TLR4 / NF-κB signal path to inhibit downstream inflammatory proteins of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and diterpenoid A and diterpenoid B both show significant anti-neuroinflammatory activity.The present application can obtain the preparation method and application of diterpenoid.

The invention belongs to the technical field of biological medicine, and particularly relates to low-molecular-weight stemona polysaccharide (STP-3-2) as well as a preparation method and application thereof, and the weight-average molecular weight (Mw) of the low-molecular-weight stemona polysaccharide (STP-3-2) is between 15 kDa and 5 kDa. The preparation method comprises the following steps: taking dry tuberous roots of stemona tuberosa, extracting to obtain non-starch total polysaccharide of stemona tuberosa, and separating and purifying to obtain the low-molecular-weight stemona tuberosa polysaccharide. The polysaccharide can obviously activate macrophages, enhance the phagocytic function of the macrophages, promote secretion of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and up-regulate expression of inducible nitric oxide synthase (iNOS), IL-6 and TNF-alpha mRNA, shows obvious immunological enhancement activity, does not have obvious toxic or side effects, and can be used for preparing the immunopotentiator. The polypeptide can be used for preparing medicines or functional foods for treating and / or preventing diseases such as immunosuppression and the like, and has a wide application prospect.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

A novel Lactobacillus rhamnosus KBL2290 strain exhibits various activities such as improving intestinal flora, anti-inflammatory, and strengthening intestinal tight junctions. The strain may increase intestinal flora of Akkermansia genus, Lactobacillus genus, Ruminococcus genus or Prevotella genus, suppress an expression of interleukin 1-beta (IL-1B), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A), suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1), suppress an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS), promote an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β), and increase an expression of Zo-1 or Occludin. A pharmaceutical composition including the strain may prevent or treat inflammatory bowel disease.

Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,where R5 isAt least one of R2-R4 or Re is halo.

The invention discloses a preparation method of alcohol-free extracted lavender polysaccharide and application of the alcohol-free extracted lavender polysaccharide in anti-aging products. The lavender polysaccharide (LAPC) is extracted from a lavender raw material by adopting a hot water extraction method in combination with a membrane separation technology, the yield is 4.8-8.6%, the polysaccharide content is 15-30%, the uronic acid content is 15-30%, and the pH value is 6.0-6.7. An anti-aging activity experiment in an aging mouse model induced by D-galactose shows that the LAPC prepared by the invention can remarkably improve the activity of antioxidant enzyme in an aging mouse body; the cell morphology of liver and kidney tissues is effectively improved; multiple serum biochemical indexes are recovered to be normal; the expression level of proinflammatory factors is reduced; the activity of acetylcholin esterase and nitric oxide synthase in brain tissues is inhibited; and the expression of a p53 / p21 protein signal channel is down-regulated. The LAPC provided by the invention has remarkable anti-aging activity. The provided preparation method of the lavender polysaccharide is simple, convenient and efficient, does not need complex chemical reagents, and has the potential of being developed into low-toxicity and efficient anti-aging cosmetics or medicine raw materials.

To provide a method for producing T cells for transplantation, by which T cells having an improved duration in vivo can be produced, to provide T cells having an improved duration in vivo, and to provide a pharmaceutical composition containing the T cells.SOLUTION: A method for producing a T cell for transplantation, comprising a step (A) of increasing an expression level of a nitric oxide synthase interacting protein in a T cell. There is also provided a T cell into which a nucleic acid having a function of improving an expression level of a nitric oxide synthase interacting protein is introduced.SELECTED DRAWING: None

Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate / nitrite levels, and inhibiting meyloperoxidase activity.

The invention relates to the technical field of microbial preparations, in particular to Pediococcus pentosaceus JYPR-2351 capable of relieving constipation caused by intestinal stress syndrome, metabiotic bacterial powder and a preparation method and application of the Pediococcus pentosaceus JYPR-2351 and the metabiotic bacterial powder. The Pediococcus pentosaceus JYPR-2351 is preserved in the China General Microbiological Culture Collection Center on October 25, 2023, and has the preservation number of CGMCC NO. The preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.28764. According to the pediococcus pentosaceus composition and the preparation method thereof, the metagen of the pediococcus pentosaceus JYPR-2351 is used for inhibiting positive neurons of nitric oxide synthase of intestinal tracts, the level of 5-hydroxytryptamine in serum is improved, the composition stability is high, and the individual difference is small.

A method comprising administering, to a subject in need thereof, an effective amount of a nucleotide effective to disrupt one or more pathways leading to sepsis. The nucleotide may be a nitric oxide disruptor effective to decrease the expression of inducible nitric oxide synthase. The nitric oxide disrupter may comprise a polynucleotide strand exhibiting at least 70% sequence identity to one of Sequence ID No. 1 through Sequence ID No. 47. Additionally or alternatively, the nucleotide may be an α disintegrin and metalloproteinase (ADAM) enzyme inhibitor effective to decrease the expression of ADAM enzyme. The ADAM enzyme inhibitor may comprise a polynucleotide strand exhibiting at least 70% sequence identity to one of Sequence ID No. 48 through Sequence ID No. 56.

The application belongs to the field of medicine, and specifically provides application of drug-loaded nanoparticles in preparation of medicine for preventing or treating atherosclerosis, wherein the drug-loaded nanoparticles comprise: (1) a polyamino acid carrier, wherein a nitric oxide donor is grafted on the polyamino acid carrier; and (2) a nucleic acid drug for silencing Camk2g gene expression, which is encapsulated in the polyamino acid carrier. The drug-loaded nanoparticles target the nucleic acid drug for silencing Camk2g gene expression to be delivered into plaque macrophages, restore the phagocytosis function of the macrophages, and then improve the microenvironment inside the plaque; meanwhile, the drug-loaded nanoparticles can also deliver the nitric oxide donor to the macrophages, and the nitric oxide donor reacts with inducible nitric oxide synthase in the macrophages to generate nitric oxide. Nitric oxide gas molecules diffuse to the vicinity of damaged endothelial cells, repair the endothelial cell barrier, restore the integrity of the vascular endothelial barrier, and play a combined treatment role, thereby achieving efficient treatment of atherosclerosis.

The invention provides a novel guanidino cyclohexane derivative as shown in a formula I, a preparation method of the novel guanidino cyclohexane derivative and application of a pharmaceutical preparation containing the novel guanidino cyclohexane derivative in drugs for treating gastric mucosal lesions. The compound has a medicine development prospect for preventing and treating reflux esophagitis by adjusting the influence of nitric oxide synthase (NOS) and anti-inflammatory activity on microcirculation.

The invention discloses an application of dendrobium huoshanense protocorm in resisting fatigue, invigorating kidney and strengthening yang. The dendrobium huoshanense protocorm is combined with the herba cistanche, the American ginseng, the raspberry, the dogwood and the fructus lycii, so that the anti-fatigue, kidney-tonifying and yang-strengthening effects of the formula can be remarkably improved. Compared with the single use of cistanche, after the addition of the dendrobium huoshanense protocorm, the exhaustive swimming time of a mouse can be obviously prolonged, the content of urea nitrogen and lactic acid in serum of the mouse is reduced, the content of hepatic glycogen in hepatic tissue is improved, and the content of muscle glycogen in muscular tissue is improved. Compared with a single use of cistanche, the dendrobium huoshanense protocorm can significantly improve the activity of superoxide dismutase in serum of rats with kidney-yang deficiency, reduce the content of malondialdehyde in the serum, improve the content of testosterone in the serum, improve the activity of nitric oxide synthase in penis tissues, and improve the content of nitric oxide and cyclic guanosine monophosphate in the penis tissues after the addition of the dendrobium huoshanense protocorm.

This invention relates to a method of fixating and stabilizing nitric oxide metabolites through fermentation of nitrogen-containing natural substance. According to the method of the invention, the fermentation efficiency is maximized by optimizing the fermentation conditions so that the productivity of nitric oxide metabolites is significantly improved. Thus, eating a fermented natural substance in which nitric oxide metabolites are fixated and stabilized by the method of the present invention would be helpful for maintaining the homeostasis of human body, in which nitric oxide synthase is either absent or insufficient, based on vasodilation and activation of a neurotransmitter and immune function as medical efficacy of nitric oxide.

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.

The present disclosure is directed to a joint-health composition containing one or more anti-inflammatory compounds in a lipid matrix, which improves bioavailability and nutrient availability of the anti-inflammatory compound, as well as allow the release of the anti-inflammatory compound to be controlled over a period of time. The anti-inflammatory compound can include an extract or isolate from a natural source that inhibits one or more of: interleukin-1 expression, interleukin-6 expression, NF-kB expression, cyclooxygenase-2 (COX-2) expression, inducible nitric oxide synthase (iNOS) expression, 5-lipoxygenase biosynthesis, and tumor necrosis factor-α (TNF-α) expression.

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.